Empiric antimicrobial therapy with aztreonam or ceftazidime in gram-negative septicemia.
Am J Med
; 80(5C): 79-84, 1986 May 30.
Article
em En
| MEDLINE
| ID: mdl-3521272
ABSTRACT
In an open, comparative study, 225 patients with severe underlying diseases and suspected gram-negative bacillary septicemia were randomly assigned to receive aztreonam or ceftazidime empirically, 2 g intravenously three times daily. Twenty-five patients in the aztreonam group and 22 in the ceftazidime group had blood cultures that grew aerobic gram-negative bacilli and were evaluable for response to therapy. All pathogenic strains were sensitive to treatment. In the aztreonam group, 22 (88 percent) patients had cures, three (12 percent) had failures, and seven (28 percent) had development of superinfections (five were caused by gram-positive cocci and two by fungi). In the ceftazidime group, 18 (82 percent) patients had cures, one had improvement, three (14 percent) had failures, and three had superinfections. The median peak serum bactericidal activity was 12,048 after aztreonam administration and 1512 after ceftazidime administration. Failures were not related to resistant strains or to low serum bactericidal activity.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Aztreonam
/
Ceftazidima
/
Sepse
/
Infecções por Enterobacteriaceae
Tipo de estudo:
Clinical_trials
/
Etiology_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Am J Med
Ano de publicação:
1986
Tipo de documento:
Article